Navigation Links
Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Date:9/14/2009

THOUSAND OAKS, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 17, 2009, in London, beginning at 9:50 a.m. Greenwich Mean Time. Amgen executives will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 (media)
    John Shutter, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
2. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
3. Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
4. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
5. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
6. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
7. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
8. Amgen to Present at the Cowen and Company Annual Healthcare Conference
9. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... and multilingual testing services, announced today the launch of its revamped and improved ... of scalable language service solutions, the redesigned website will better communicate how the ...
(Date:2/9/2016)... NJ (PRWEB) , ... February 09, 2016 , ... ... Dorman, former Vice President for Public Policy for the National Organization for Rare ... patient advocacy groups to ensure their voices are heard throughout the drug regulatory ...
(Date:2/9/2016)... 2016 BERG, a biopharmaceutical company uncovering ... has announced the appointment of Jason Haddock ... Officer. Haddock brings to BERG over 20 years ... in senior financial functions at pharmaceutical companies, as ... management. Niven R. Narain , ...
(Date:2/8/2016)... 8, 2016 --> ... an innovation-driven oncology company developing next generation cancer ... today announced that chairman emeritus of Tata Sons ... the company as part of the first close ... investors Navam Capital and Aarin Capital. ...
Breaking Biology Technology:
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
Breaking Biology News(10 mins):